Back to search results

Research Study on CagriSema and Semaglutide for Weight Loss in Obesity

This study is looking at how two different doses of CagriSema and one dose of Semaglutide help people with obesity, with or without type 2 diabetes (T2D), lose weight. CagriSema is a new medicine being tested, while Semaglutide is a medicine doctors can already prescribe. You would receive either CagriSema or Semaglutide by chance. The main goal is to see how much body weight changes over 72 weeks. To join, you must be at least 18 years old with a body mass index (BMI) of 35.0 kg/m² or higher. If you have T2D, your HbA1c (a measure of blood sugar) must be less than 10%; if not, your HbA1c must be less than 6.5%. The study aims to enroll 2500 participants and will last about 83 weeks.

Study design
This is an interventional study comparing two different doses of CagriSema and one dose of Semaglutide. Participants are randomly assigned to receive one of these treatments.
What's involved
You would receive study medication administered subcutaneously (under the skin). The study will last for about 83 weeks.
Compensation
Not stated in the trial record.
Follow-up
Your body weight will be measured from the start of the study (randomization at week 0) until the end of treatment (week 72).

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07564414

A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight

Recruiting
PHASE3Ages 18+InterventionalTreatment
Novo Nordisk A/S
~2,500 participants
Updated 2026-07-30 on ClinicalTrials.gov
What's tested:CagrisemaSemaglutide

At a glance

Recruiting sites
161 of 303 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Relative change in body weight
Measured over From randomisation (week 0) to end of treatment (week 72)

Conditions

Obesity
Type 2 Diabetes

Explore related trials

ObesityType 2 Diabetes Mellitus

Where it's being run

303 sites across 80 states
Texas19
Poland15
Bulgaria14
Greece13
Spain13
California11
Florida10
Argentina10

Study leadership

  • Clinical Transparency (dept. 2834) · STUDY_DIRECTOR · Novo Nordisk A/S

Who to contact

Novo Nordisk
[email protected]
(+1) 866-867-7178
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Male or female (sex assigned at birth, inclusive of all gender identities).
Age 18 years or above at the time of signing the informed consent.
BMI≥ 35.0 kg/m\^2.
Participants without T2D: No history of T2D and HbA1c \< 6.5% (48 millimoles per mole (mmol/mol)) Participants with T2D: A history of T2D and HbA1c \< 10% (\< 86 mmol/mol). If a participant without a history of diabetes during the screening period receives an HbA1c result of 6.5% (48 mmol/mol) or higher, the investigator or the participant's healthcare provider must confirm the diagnosis of type 2 diabetes before the participant is randomised.

Exclusion

A self-reported change in body weight \> 5% within 90 days before screening, irrespective of medical records.
Use of any glucagon-like-peptide-1 receptor agonist (GLP-1 RA), including medication with GLP-1 RA activity, or amylin analogues, including medication with amylin activity, within 6 months before screening.

What this trial measures

  • Relative change in body weightFrom randomisation (week 0) to end of treatment (week 72)

    Measured as percentage (%).